Adam JacksonJanuary 3, 2024
The firm is targeting the FDA’s 505(b)(2) pathway for a potentially expedited approval process.
Tag: ketamine
Adam JacksonJanuary 3, 2024Adam JacksonNovember 27, 2023
Positive study results could prompt Seelos to seek FDA approval for its drug.
John SchroyerNovember 8, 2023Pain and depression top the list of conditions being treated with the psychedelic drug.
John SchroyerNovember 1, 2023
To facilitate the acquisition, Beckley founded a new subsidiary, NueCo Holdings PBC.
Debra BorchardtOctober 27, 2023
This week three doctors reviewed the test results comparing the two options for treatment-resistant depression (TRD). Electroconvulsive therapy (ECT) is considered the gold standard for TRD but is not widely used in the U.S. Ketamine infusion has gained more attention in the U.S. as a treatment for TRD as a rapid-acting option, but also one […]
StaffOctober 12, 2023
Research has shown ketamine to have rapid antidepressant effects.
Debra BorchardtOctober 12, 2023
Spravato is the only FDA-approved version of ketamine that isn't injectable.
Debra BorchardtSeptember 20, 2023Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced top-line data demonstrating clinically meaningful treatment effects across multiple endpoints and a well-tolerated safety profile from the double-blind, placebo-controlled cohort (Part 2) of its Phase II study of SLS-002 (intranasal racemic ketamine) for Acute Suicidal Ideation and Behavior (ASIB) in adults with Major Depressive Disorder (MDD). However, while Montgomery-Åsberg […]
Debra BorchardtAugust 30, 2023The company acknowledged it needed additional funding to continue operations.
John SchroyerAugust 9, 2023Two-thirds of participants with major depressive disorder or generalized anxiety disorder reported improvement.
Get the latest cannabis news delivered right to your inbox
Unpack the industry with the daily cannabis newsletter for business leaders.